Laman UtamaLAURUSLABS • NSE
Laurus Labs Ltd
₹562.35
13 Jan, 3:53:27 PTG GMT+5:30 · INR · NSE · Penafian
SahamSekuriti tersenarai IN
Tutup sebelumnya
₹583.70
Julat hari
₹555.90 - ₹586.00
Julat tahun
₹360.85 - ₹619.40
Permodalan pasaran
301.43B INR
Bilangan Purata
1.91J
Nisbah P/E
231.15
Hasil dividen
0.14%
Pertukaran utama
NSE
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(INR)Sep 2024Perubahan T/T
Hasil
12.24B-0.06%
Perbelanjaan pengendalian
6.05B10.51%
Pendapatan bersih
198.40J-46.31%
Margin untung bersih
1.62-46.36%
Pendapatan bagi setiap syer
0.37-45.59%
EBITDA
1.78B-5.65%
Kadar cukai berkesan
20.33%—
Jumlah aset
Jumlah liabiliti
(INR)Sep 2024Perubahan T/T
Pelaburan tunai dan jangka pendek
449.20J-33.11%
Jumlah aset
87.29B8.34%
Jumlah liabiliti
45.85B14.21%
Jumlah ekuiti
41.44B—
Syer tertunggak
536.22J—
Harga kepada buku
7.57—
Pulangan pada aset
——
Pulangan pada modal
2.60%—
Perubahan bersih dalam tunai
(INR)Sep 2024Perubahan T/T
Pendapatan bersih
198.40J-46.31%
Tunai daripada operasi
——
Tunai daripada pelaburan
——
Tunai daripada pembiayaan
——
Perubahan bersih dalam tunai
——
Aliran tunai bebas
——
Perihal
Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients, generic formulations, custom synthesis, biotechnology, veterinary APIs and agrochemicals. The company was founded in 2005 by Satyanarayana Chava. Laurus Labs has its eight manufacturing plants located at Visakhapatnam, Hyderabad and Bangalore. The manufacturing units have received one or more approvals from USFDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA. The company operates through its subsidiaries in Europe and United States and also offers its services in contract research, clinical research and analytical research through its R&D centers. The R&D centres are based in Hyderabad, Visakhapatnam and United States. Wikipedia
Diasaskan
2005
Pekerja
6,007
Cari
Kosongkan carian
Tutup carian
Apl Google
Menu utama